Natera, Inc. (NASDAQ:NTRA) Insider Sells $40,533.39 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 291 shares of Natera stock in a transaction on Monday, July 21st. The shares were sold at an average price of $139.29, for a total transaction of $40,533.39. Following the completion of the sale, the insider owned 128,265 shares in the company, valued at approximately $17,866,031.85. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, May 27th, Solomon Moshkevich sold 1,649 shares of Natera stock. The shares were sold at an average price of $156.85, for a total transaction of $258,645.65.
• On Tuesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $166.77, for a total transaction of $500,310.00.
• On Monday, June 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $157.07, for a total value of $471,210.00.
• On Thursday, May 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $150.12, for a total transaction of $450,360.00.
• On Monday, April 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The stock was sold at an average price of $152.18, for a total transaction of $335,709.08.

Natera Price Performance

Shares of NTRA traded up $3.25 during mid-day trading on Thursday, reaching $141.07. The stock had a trading volume of 1,421,449 shares, compared to its average volume of 1,212,550. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00. The firm has a market cap of $19.26 billion, a price-to-earnings ratio of -95.97 and a beta of 1.73. The business's fifty day moving average is $159.24 and its 200 day moving average is $157.55.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same period in the prior year, the business posted ($0.56) EPS. The business's revenue for the quarter was up 36.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after acquiring an additional 77,357 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after buying an additional 660,538 shares during the last quarter. Wellington Management Group LLP raised its stake in Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after acquiring an additional 439,778 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Natera by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after purchasing an additional 142,201 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group raised their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Piper Sandler boosted their target price on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.